Latest news
{{'2026-11-08T18:45:00Z' | dateFormatFilter}}
Novo post hoc analysis finds Wegovy 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026
{{'2026-11-06T20:00:00Z' | dateFormatFilter}}
Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
{{'2026-11-04T06:30:47Z' | dateFormatFilter}}
Novo raises full-year outlook on continued GLP-1 momentum, with third-quarter adjusted operating profit increasing 27% at CER to DKK 31,720 million
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
